Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
Keywords: جمسیتابین; Chemotherapy; Gemcitabine; Paclitaxel; Vinorelbine; Non-small cell lung cancer; Cost-minimisation; Pharmacoeconomics;